Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)
Taiwan · Delayed Price · Currency is TWD 30.70
0.00 (0.00%)
May 29, 2026, 1:30 PM CST
Sinphar Pharmaceutical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 327.17 | 365.75 | 304.71 | 375.17 | 224.64 | -38.14 |
Depreciation & Amortization | 241 | 241.61 | 243.47 | 230.04 | 248.7 | 247.33 |
Other Amortization | 12.72 | 12.72 | 13.9 | 13.49 | 18.01 | 22.04 |
Loss (Gain) From Sale of Assets | 0.72 | 1.05 | 2.48 | -5.13 | 0.81 | 1.5 |
Loss (Gain) From Sale of Investments | -0.09 | -0.12 | -0.3 | - | - | - |
Provision & Write-off of Bad Debts | 0.06 | - | 0.14 | 1.68 | 0.47 | 2.54 |
Other Operating Activities | 8.67 | -5.87 | -3.62 | -187.15 | -26.55 | -190.8 |
Change in Accounts Receivable | 5.41 | -80.44 | -17.7 | 27.29 | -73.59 | -84.1 |
Change in Inventory | -27.9 | -9.78 | 124.29 | -102.18 | -39.62 | -15.95 |
Change in Accounts Payable | -4.33 | 25.13 | -106 | -31.97 | 121.92 | 7.05 |
Change in Unearned Revenue | 12.82 | 5.93 | 11.77 | -10.91 | 2.92 | -4.16 |
Change in Other Net Operating Assets | 60.86 | 28.67 | 20.37 | -13.95 | -52.42 | 188.24 |
Operating Cash Flow | 637.12 | 584.66 | 593.51 | 296.37 | 425.3 | 135.54 |
Operating Cash Flow Growth | 6.51% | -1.49% | 100.26% | -30.31% | 213.77% | -7.41% |
Capital Expenditures | -265.24 | -194.71 | -240.44 | -295.51 | -141.48 | -146.18 |
Sale of Property, Plant & Equipment | 0.05 | 0.05 | 0.48 | 6.3 | 0.24 | 0.53 |
Sale (Purchase) of Intangibles | -8.11 | -6.24 | -16.28 | -5.43 | -11.96 | -15.26 |
Investment in Securities | 46.43 | -29.35 | -136.62 | -2.45 | 33.76 | 0.33 |
Other Investing Activities | 5.22 | 5.62 | 1.77 | -37.48 | -4.8 | -45.02 |
Investing Cash Flow | -221.65 | -224.63 | -391.08 | -334.56 | -124.24 | -205.6 |
Short-Term Debt Issued | - | - | - | - | - | 35 |
Long-Term Debt Issued | - | - | 50 | 160 | 180 | 85 |
Total Debt Issued | 210 | - | 50 | 160 | 180 | 120 |
Short-Term Debt Repaid | - | -182 | -30 | -47 | -140 | - |
Long-Term Debt Repaid | - | -211.89 | -62.36 | -81.1 | -259.07 | -138.92 |
Total Debt Repaid | -323.34 | -393.89 | -92.36 | -128.1 | -399.07 | -138.92 |
Net Debt Issued (Repaid) | -113.34 | -393.89 | -42.36 | 31.9 | -219.07 | -18.92 |
Issuance of Common Stock | - | - | - | - | - | 15.58 |
Common Dividends Paid | -181.14 | -181.14 | -167.72 | -167.72 | -33.54 | -33.54 |
Other Financing Activities | -1 | -1 | 1 | 15.15 | -10.72 | 159.83 |
Financing Cash Flow | -295.48 | -576.03 | -209.08 | -120.67 | -263.33 | 122.95 |
Foreign Exchange Rate Adjustments | 8.63 | 4.46 | 7.83 | -4.2 | 5.04 | -1.88 |
Net Cash Flow | 128.62 | -211.53 | 1.18 | -163.07 | 42.77 | 51.02 |
Free Cash Flow | 371.88 | 389.95 | 353.08 | 0.86 | 283.82 | -10.64 |
Free Cash Flow Growth | -12.93% | 10.45% | 40955.23% | -99.70% | - | - |
Free Cash Flow Margin | 10.96% | 11.57% | 11.21% | 0.03% | 9.93% | -0.44% |
Free Cash Flow Per Share | 1.95 | 2.04 | 1.85 | 0.01 | 1.49 | -0.06 |
Cash Interest Paid | 34.15 | 34.15 | 36.49 | 33.65 | 27.64 | 24.86 |
Cash Income Tax Paid | 41.91 | 41.91 | 5.3 | 57.37 | 47.1 | 44.35 |
Levered Free Cash Flow | 295.41 | 279.33 | 232.08 | -125.83 | 206.61 | 65.95 |
Unlevered Free Cash Flow | 315.45 | 300.48 | 255.06 | -104.76 | 223.99 | 81.45 |
Change in Working Capital | 46.87 | -30.49 | 32.73 | -131.73 | -40.79 | 91.08 |